A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).
Vito Lorusso, Giuseppe Colucci(University of Basel), Roberto Bordonaro(Ospedale Garibaldi), Saverio Cinieri(Ospedale A. Perrino), Vittorio Gebbia(Università degli Studi di Enna Kore), Luciana Petrucelli(Ospedale Vito Fazzi), Salvatore Pisconti(Ospedale SS. Annunziata), Gianfranco Filippelli(Presidio Ospedaliero), Mariangela Ciccarese(Ospedale Vito Fazzi), Salvatore Del Prete(Federico II University Hospital), R. Forcignano, Evaristo Maiello(Casa Sollievo della Sofferenza), Francesco Giotta(Istituto Tumori Bari), Vincenzo Emanuele Chiurì, S. Romito(Ospedali Riuniti di Foggia), Giuseppe Cairo(Ospedale Vito Fazzi), V. Saracino(Ospedale Vito Fazzi), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234